Advancing mRNA Science – We’re Attending the mRNA-Based Therapeutics Summit in Boston

Advancing mRNA Science – We’re Attending the mRNA-Based Therapeutics Summit in Boston

From July 21st to 23rd, 2025, Boston will host one of the most influential gatherings in the field of mRNA innovation: the mRNA-Based Therapeutics Summit USA.

We’re excited to announce that our team will attend the event as visitors, eager to immerse ourselves in the latest developments shaping the future of mRNA-based medicines.

The summit brings together over 500 industry leaders, from biotech pioneers and CDMOs to academic researchers and regulatory authorities. Across three days, key discussions will focus on:

  • The next generation of mRNA delivery technologies

  • Scalable, cost-effective manufacturing solutions

  • Clinical progress in infectious diseases, oncology, and rare conditions

  • Regulatory trends and quality standards shaping the industry

For us, this is more than just a conference — it’s a chance to stay aligned with the pulse of mRNA innovation, build new relationships, and gather valuable insights to bring back to our own operations.

If you’ll be in Boston too and would like to connect, don’t hesitate to reach out. We look forward to learning, exchanging ideas, and being part of the conversations that will define the next chapter of mRNA therapeutics.

See you in Boston!

image mRNA Based Therapeutics Summit
1200 900 Anemocyte.com

Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131

VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961